Lorbrena

GPTKB entity

Statements (39)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:approvalYear 2018
gptkbp:approvedBy gptkb:PMDA
gptkb:FDA
gptkb:EMA
gptkbp:ATCCode L01ED10
gptkbp:brand gptkb:Lorbrena
gptkb:Lorviqua
gptkbp:CASNumber 1454846-35-5
gptkbp:chemicalFormula C21H19FN6O2
gptkbp:developedBy gptkb:Pfizer
gptkbp:eliminationHalfLife 20.6 hours
gptkbp:genericName gptkb:lorlatinib
https://www.w3.org/2000/01/rdf-schema#label Lorbrena
gptkbp:indication gptkb:non-small_cell_lung_cancer
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction ALK inhibitor
ROS1 inhibitor
gptkbp:metabolism gptkb:CYP3A4
gptkbp:molecularWeight 406.42 g/mol
gptkbp:pregnancyCategory Not assigned
gptkbp:prescribes ALK-positive metastatic non-small cell lung cancer
ROS1-positive metastatic non-small cell lung cancer
gptkbp:proteinBinding 66%
gptkbp:routeOfAdministration oral
gptkbp:sideEffect gptkb:familial_hypercholesterolemia
edema
hypertension
weight gain
peripheral neuropathy
QT prolongation
hepatotoxicity
cognitive effects
arthralgia
interstitial lung disease
hypertriglyceridemia
mood effects
gptkbp:bfsParent gptkb:lorlatinib
gptkbp:bfsLayer 6